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Introduction:  Infectious  causes  are  a signiﬁcant  contributor  to morbidity  and  mortality  in  neonates  and
young  infants.  Immunization  of  pregnant  women  to protect  the  mother  and/or  her infant  is gaining
momentum  due  to the beneﬁts  of this  strategy  demonstrated  in  numerous  implemented  strategies
(Maternal  and Neonatal  Tetanus  Elimination  Initiative)  and  clinical  trials.
Reluctance  by  regulators,  participants  and  healthcare  providers  to include  pregnant  women  in clinical
trials  is  considerable,  but  reducing.  Infectious  disease  burden,  and therefore  need  for  interventions  to
reduce  morbidity  and  mortality  in  mothers  and  infants,  is  highest  in low-middle  income  countries  (LMIC),
however,  reliable  background  data  on  adverse  pregnancy  outcomes  and lack  of  experience  in  clinical  trials
and community  opinions  on  immunization  during  pregnancy  are not  well  documented.
Methods:  We  used  our  experiences  in  conducting  two  clinical  studies  in pregnant  women  in South  Africa
to  illustrate  the  challenges  experienced  and  lessons  learnt  which  may  beneﬁt  others  working  in the
maternal  immunization  ﬁeld.
Results:  Accurate  gestational  age  assessment,  which  is  essential  for clinical  trials,  is challenging  in LMIC
due  to  limited  access  to early  ultrasound  examinations,  and  unreliable  assessment  by history  (last  men-
strual  period  date)  and physical  examination  (symphyseal-fundal  height).
Concomitant  administration  of recommended  vaccines  has  previously  been  avoided  in clinical  trials;
however,  this  limitation  could  impact  the  potentially  beneﬁcial  interventions  that participants  can  access
during  antenatal  care.
Women  in  LMIC  have  a  higher  burden  of concomitant  illnesses  (e.g.  HIV  infection,  malaria  and  anaemia)
and  adverse  pregnancy  outcomes  (e.g.  stillbirth)  than  pregnant  women  in higher  income  countries.  Avail-
ability  of  local  data  is  essential  for safety  monitoring  committees  to identify  vaccine-related  adverse  event
triggers.
Conclusion:  Immunization  of  pregnant  women  to reduce  disease  burden  in them  and  their  infants  is
promising,  and  women  in high-risk  settings  should  be included  in trials (Clinical  trial  registry  number:
‘Study  A’:  NCT01193920,  ‘Study  B’: NCT01888471).
ublis© 2015  The  Authors.  P∗ Corresponding author at: Medical Research Council: Respiratory and Meningeal
athogens Research Unit, Johannesburg, South Africa. Tel.: +27 11 9834283;
ax: +27 86 6740564.
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. IntroductionThe greatest burden of infection-related morbidity and mortal-
ity in pregnant women, neonates and young infants is concentrated
in low-middle income countries (LMIC), where access to health-
care is limited [1]. Pregnancy is associated with changes in the
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mmune system which could contribute to increased susceptibility
o infectious diseases including inﬂuenza and malaria [2]. Neonatal
eaths currently account for 44% of the 6.3 million annual under-
 year deaths globally; 23% of which are due to sepsis, meningitis
r pneumonia [1]. In addition, a substantial burden of infection-
elated mortality in children age 1–59 months old occurs in the
rst 6 months of life, when infants are generally too young to fully
eneﬁt from vaccination, even when an accelerated immunization
chedule is used.
Global tetanus toxoid immunization coverage with two  doses
uring pregnancy was 65% in 2013. This, together with an increase
n the presence of skilled birth attendants at deliveries (enhanc-
ng safe and hygienic parturition practices), has reduced neonatal
etanus cases from approximately 490 000 in 1994 to 49 000 in 2013
3]. This experience highlights the potential of vaccination of preg-
ant women for control of infectious diseases in their neonates.
ore recently, inﬂuenza vaccination of pregnant women has been
ssociated with reduced illness in mothers, and their infants up
o 6 months of age [4,5]. Vaccination of pregnant women with
cellular pertussis vaccines during a recent pertussis outbreak in
ngland was associated with approximately 90% decline in pertus-
is illness among young infants of vaccinated mothers [6]. There
as been an upsurge of clinical vaccine trials speciﬁcally targeting
regnant women with the primary objective of reducing morbidity
nd mortality in young infants [7], as well as potentially beneﬁt-
ng the mother and improving birth outcomes. Vaccines are being
eveloped speciﬁcally for immunization of pregnant women to
rotect their infants, including Group B Streptococcus (GBS) and
espiratory syncytial virus (RSV) vaccines.
Despite absence of safety concerns for vaccines, including
nactivated inﬂuenza vaccine (IIV), tetanus toxoid and acellular
ertussis vaccines, which are recommended during pregnancy [8],
here remains reluctance among pregnant women and healthcare
roviders to vaccinate during pregnancy [9]. Regulatory bodies and
nstitutional review boards historically excluded pregnant women
rom investigational vaccine and drug studies; however, more
ecent regulation stipulates their inclusion in some clinical studies
10].
The United States Food and Drug Administration Center for Bio-
ogics Evaluation and Research encourages sponsors to include
articipants from the USA in maternal immunization clinical tri-
ls leading to USA licensure [11]. The incidence of certain diseases
uch as invasive early-onset GBS disease (GBS-EOD), however, has
eclined in USA through alternate strategies (intrapartum antibi-
tic prophylaxis), necessitating consideration of conducting pivotal
linical endpoint efﬁcacy trials in low-middle income countries
LMIC) where the burden of disease favours the practicality of
ompleting such studies. There is limited experience of conduct-
ng maternal immunization trials globally, and the acceptability by
omen and their families, of partaking in these trials is unknown.
The aims of this manuscript are to (i) describe chal-
enges encountered during the implementation of clinical studies
nrolling pregnant women and their infants in a LMIC setting and
ii) provide proposals on mitigation of these challenges, thereby
acilitating research in pregnant women required for approval of
accines speciﬁcally for this population.
. Methods
.1. Study settingThis report highlights some of the challenges and learning expe-
iences from two clinical studies conducted in Soweto, South Africa:
 double-blinded, randomized, placebo-controlled trial (RCT) of
 trivalent GBS-conjugate vaccine (serotypes Ia, Ib and III) in3 (2015) 6406–6412 6407
pregnant and non-pregnant HIV-uninfected women (‘Study A’,
clinicaltrials.gov: NCT01193920), and an observational pilot study
involving pregnant women and their infants to assess the feasibil-
ity of conducting a larger GBS study (‘Study B’, clinicaltrials.gov:
NCT01888471). The studies were undertaken at Chris Hani Barag-
wanath Academic Hospital (CHBAH); a public secondary-tertiary
hospital in Soweto, an urban area south of Johannesburg. CHBAH
offers free maternity and child care [12] to a population of 1.2
million people [13]. The annual birth cohort of Soweto is approx-
imately 29 000 [14] with 75% of deliveries occurring at CHBAH
and the remainder at one of 6 community-based midwife obstetric
units. Antenatal clinics offer voluntary counselling and testing for
HIV, which is accepted by >96% of attendees (Personal communi-
cation: C. Mnyani).
The incidence of GBS-EOD has remained consistently at 1.37–2.0
per 1000 live births since the mid-1990s to 2013, with GBS
serotypes Ia, Ib and III responsible for 80–88% of GBS invasive dis-
ease [15–17].
2.2. ‘Study A’
Study A was  conducted between September 2010 and December
2012. Maternal participants were healthy, HIV-uninfected, preg-
nant women aged 18–40 years, at 28–35 weeks gestation (n = 320).
Gestational age was  estimated by ultrasonography prior to 24
weeks gestation if available; alternately according to in-house stan-
dard operating practice reviewing date of last menstrual period,
symphyseal-fundal height or later ultrasonography. Exclusion cri-
teria included vaccination (other than IIV or tetanus) within 30 days
prior to enrolment, high-risk pregnancy, receipt of blood prod-
uct within 12 weeks of screening, history of reaction to vaccine
component, or other serious illnesses. Participants were random-
ized in a 1:1:1:1 ratio to receive one injection of 0.5, 2.5, or 5.0 g
non-adjuvanted vaccine formulation, or placebo and maternal and
infant participants were followed up regularly until 12 months
post-delivery (Table 1).
2.3. ‘Study B’
‘Study B’ was an observational pilot study enrolling women
delivering at CHBAH to determine (1) the feasibility of key oper-
ational aspects of a maternal study including enrolment rates,
sample collection and data availability; (2) serotype distribution of
GBS isolates colonizing mothers at delivery and from infants with
invasive GBS disease. In brief, women  aged ≥18 years attending
routine antenatal care or delivering at CHBAH between December
2013 and June 2014 were prospectively enrolled. Maternal demo-
graphic and gestational age data were collected at enrolment.
Medical and obstetric history, labour and delivery details and
maternal- and cord blood were collected at delivery. A subset of
women had a vaginal swab taken at delivery to assess prevalence
and serotype distribution of GBS colonization.
2.4. Regulatory approval
Both studies were approved by the Human Research Ethics Com-
mittee (HREC), University of the Witwatersrand (HREC references
100502 and 130407). ‘Study A’ was  also approved by the Medicines
Control Council of South Africa (reference 20100601). Neither regu-
latory authority raised concerns about these studies, despite study
‘A’ being the ﬁrst GBS vaccine trial in pregnant women. Studies were
designed and implemented according to the International Confer-
ence on Harmonisation Guidelines for Good Clinical Practice, with
applicable local regulations, and the Declaration of Helsinki.
Women  signed informed, written consent prior to any proce-
dures being conducted in Study A. Vaccination visit was 0–14 days
6408 C.L. Cutland et al. / Vaccine 3
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post consenting. In Study B, for women enrolled during labour, the
HREC approved cord blood collection to occur prior to consenting,
which was  then deferred until post-delivery when the mother was
able to engage in the consenting process. Classiﬁcation of labour
as a time of ‘duress’ during which consenting for research study
inclusion is not practical or ethical, and the non-invasive nature of
cord blood collection were considered prior to HREC approval. Cord
blood samples collected, for which consent was subsequently not
obtained, were destroyed. Maternal blood samples were obtained
following informed consenting process. HREC does not require con-
sent from both parents due to the high proportion of single-parent
families, and the absence of male partners at ante-natal visits and
delivery.
2.5. Data analysis
Baseline characteristics of participants were summarized using
descriptive statistics, and frequency distributions for categorical
variables. Differences in mean values were tested using a one tailed
t-test assuming equal variance of independent samples. Data entry
and analyses were completed using InFormTM, SAS – Statistical
Analysis Software or Microsoft Excel.
3. Challenges encountered
3.1. Gestational age assessment
Immunization studies in pregnant women  require accurate
assessment of gestational age. Immunization in the ﬁrst trimester
is usually avoided as the risks to foetal development are high-
est in this period. Timing of vaccine administration in the second
and third trimesters should allow for induction of adequate mater-
nal antibody responses and trans-placental antibody transfer prior
to delivery. A narrow vaccination window may  be required to
optimize transplacental antibody transfer. The ﬁnal duration of
pregnancy is an important trial outcome as it is a strong predictor
of infant survival [18].
In our experience, accurate assessment of gestational age was
challenging. Pregnancy dating in South African public health care
facilities is primarily by history and clinical assessment, utilizing
last menstrual period (LMP) dates and symphyseal-fundal height
measurements [19].
Use of LMP  for gestational age assessment is advantageous due
to its universal availability, simplicity and low cost. LMP  use, how-
ever, relies on accurate self-reporting by the pregnant mother [20],
which is often not feasible for numerous reasons including (i) irreg-
ular menstrual cycle length or preconception amenorrhoea, often
related to disruption of menstrual bleeding patterns caused by
injectable contraceptives [21], (ii) unrecognized miscarriages and
(iii) recall error [20,22].
Most women attending antenatal clinic in South Africa have
serial symphyseal-fundal height measurements performed; how-
ever, there is high intra- and inter-observer variability and poor
reproducibility [23], therefore limiting its accuracy and useful-
ness. Obesity, which is common (44%) amongst pregnant women is
South Africa [24], reduces accuracy of gestational age assessment
by symphyseal-fundal height measurements.
Over 50% of pregnancies in Johannesburg were reported as being
unplanned [25], and in spite of high levels of ANC coverage, late
presentation for ANC care in the second trimester is still frequent
[23]. The mean age at antenatal booking in Study B participants was
20.4 weeks (Table 3).
In Study B, 70% (1868/2669) of participants did not have an ultra-
sound gestational age assessment during pregnancy. In Study B,
expected gestational age at delivery extrapolated from antenatal
C.L. Cutland et al. / Vaccine 3
Table  2
Gestational age assessments of participants enrolled antenatally into an observa-
tional study.
Gestational age (weeks) at enrolment in ANC Mean SD
N = 92
GA by any method 33.9 4.8
GA  by LMP  (n = 31; 34%) 35.8 4.2
GA  by ultrasound (n = 52, 57%) 32.4 4.7
GA  by fundal height (n = 9, 10%) 35.8 5.2
Difference in weeks from GA at enrolment versus GA at delivery %
N = 92
Discrepancy of >2 weeks GA any assessment 45/92 49
Discrepancy of >2 weeks GA LMP 19/31 61
Discrepancy of >2 weeks GA ultrasound 20/52 38
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a global prevalence of 38%, but as high as 56% in some regions [28].
T
HDiscrepancy of >2 weeks GA fundal height 6/9 67
ssessment and gestational age measured at delivery were com-
ared. Although numbers available for comparison were limited
N = 92), a discrepancy of >2 weeks between expected- and actual
estational age was more commonly observed when initial gesta-
ional age antenatal measurements were made using LMP  (61%) and
ymphyseal-fundal height (67%) compared with ultrasound (38%).
South African guidelines recommend ultrasound before 24
eeks of gestational age [26], however, in Study B, 49% (661/1338)
nd 31% (421/1338) of women initiated antenatal care at or after
0 or 24 weeks gestation, respectively.
Recent studies from South Africa [19] and Brazil [20] suggest
hat ultrasound assessments up to the 28–30 weeks gestational age
ere more accurate at assessing gestational age than LMP  and/or
ymphyseal-fundal height measurements. Ultrasound assessments
erformed up to 28 weeks gestation should be considered accept-
ble for gestational age assessments for trial enrolment.
The protocol for Study A was amended to widen the ran-
omization window from 30–34 weeks to 28–35 weeks, which
ncreased the eligible population and still provided sufﬁcient time
or an immune response to the vaccine and transplacental anti-
ody transfer to the foetus. In clinical sites where facilities and
xpertise to conduct gestational age assessment by ultrasound are
imited, provision of ultrasound machines and local staff training,
r allowance for compensation of appropriately trained non-study
ersonnel to conduct ultrasound examinations, should be con-
idered. These challenges should be considered by the Brighton
ollaboration during development of levels of diagnostic cer-
ainty for adverse events following maternal immunization is
n which gestational age assessment is important (e.g. preterm
abour).
able 3
aemoglobin levels in pregnant women at the time of enrolment for antenatal care.
At antenatal booking 
Haemoglobin (Hb) Mean (SD) 
Gestational age at Hb measurement Mean (SD) 
Anaemic (Hb < 11 g/dL) N (%) 
Anaemic (Hb < 10.5 g/dL) N (%) 
Moderately anaemic (Hb < 10.0 g/dL) N (%) 
Moderately anaemic (Hb < 9.5 g/dL) N (%) 
Hb  in ﬁrst trimester (0–12 weeks) Mean (SD) 
Hb  in second trimester (13–28 weeks) Mean (SD) 
Hb  in third trimester (29–40 weeks) Mean (SD) 
a N = 21 subjects did not have HIV status available.3 (2015) 6406–6412 6409
3.2. Co-administration of other vaccines
The Maternal and Neonatal Tetanus (MNT) Elimination Initiative
has made remarkable progress in reducing MNT, and has high-
lighted challenges in immunizing pregnant women, especially in
areas affected by adverse political or social circumstances [3].
Other vaccines, including IIV and acellular pertussis vaccines [7]
are recommended for prevention of infections in pregnant women
and their infants, however uptake of immunization of pregnant
women remains sub-optimal. This is likely due to under-estimation
of disease risk and vaccine beneﬁts for both mother and foetus and
fears about vaccine safety in pregnancy [9]. Beneﬁts of vaccinating
pregnant women against diseases to which they are expected to be
exposed during pregnancy, however, generally outweigh potential
vaccine-related risks [8,27].
Restrictions regularly imposed in clinical trials preventing con-
current administration of licensed, recommended vaccines and
investigational vaccine should be reviewed. Investigational- and
recommended vaccines could be administered concurrently but
in different body sites, and local reactions at vaccine administra-
tions sites should be recorded on diary cards. Depending on study
design and nature of concomitant vaccine, the risk of more common
or more severe systemic reactions and immunogenicity interfer-
ence on investigational vaccine can be evaluated when concomitant
vaccine is given with or without investigational vaccine.
In Study A, tetanus toxoid and IIV administration was restricted
to >15 days pre- or post-administration of investigational vac-
cine; however, a protocol amendment, which allowed concomitant
administration of these recommended vaccines reduced study
exclusions.
3.3. Diseases in pregnancy
The health of the pregnant woman and placenta are important
determinants of the health of mother and newborn. Conducting
clinical trials in LMIC, presents investigators with the challenge
of involving participants with diseases including HIV, malaria and
anaemia which are more prevalent or more severe than in other
regions. Concomitant medication administered for these diseases
needs to be considered.
3.3.1. Anaemia
Anaemia in pregnancy (haemoglobin <11 g/dL) is common withDespite improvements in haemoglobin concentrations between
1995 and 2011, the global mean haemoglobin (Hb) concentra-
tion in pregnant women  is only 11.4 g/dL, with South Asia and
Overall HIV-uninfected HIV-infected
(n = 1365a) (n = 948) (n = 397)
11.5 (1.8) 11.8 (1.7) 11.0 (1.8)
20.4 (7.6) 20.5 (7.7) 20.0 (7.5)
495 (36.3%) 296 (31.2%) 192 (48.4%)
378 (27.7%) 219 (23.1%) 152 (38.3%)
243 (17.8%) 133 (14.0%) 106 (26.7%)
166 (12.2%) 92 (9.7%) 71 (17.9%)
(n  = 247) (n = 171) (n = 74)
12.3 (1.7) 12.5 (1.7) 11.8 (1.7)
(n  = 925) (n = 636) (n = 276)
11.4 (1.7) 11.7 (1.7) 10.9 (1.8)
(n  = 173) (n = 127) (n = 41)
10.9 (1.7) 11.1 (1.7) 10.3 (1.5)
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entral- and west Africa having the largest numbers of anaemic
xpectant mothers [28]. Study B participants mimic  these global
umbers (mean Hb = 11.5 g/dL, 36.3% anaemic, Table 3), however,
aternal HIV-infection signiﬁcantly impacted haemoglobin level
mean Hb in HIV-negative = 11.8 g/dL vs. HIV-positive = 11.0 g/dL,
 < 0.001, Table 3).
Risk factors which signiﬁcantly increase incidence of anaemia in
regnant women include malaria [29], HIV-infection [29], rural res-
dence [30], intestinal parasitic infections [30], inadequate dietary
ntake of iron [31], age of mother (<20 or >34 years) [29], recur-
ent pregnancies and short inter-pregnancy intervals. Most of these
isk factors are more prevalent in women living in developing
egions.
Anaemia in pregnancy peaks in at 30–32 weeks gestation [32],
hich often coincides with enrolment window for vaccine trials
n pregnant women. The haemoglobin level included as an inclu-
ion criteria for ‘Study A’ was adjusted from 10.5 g/dL to 9.5 g/dL
n a protocol amendment to allow for enrolment of generally well
regnant women.
.3.2. Human immunodeﬁciency virus
Representing 69% of the global HIV burden, Sub-Saharan Africa
ontinues to be the most affected region in the HIV epidemic [33].
n South Africa, almost 30% of pregnant women are HIV-infected
34]; Study B was  representative of the population, with 29.5% of
others being HIV-infected (Table 3).
Research trials are usually conducted among healthy partici-
ants with no co-morbidities, leading to exclusion of HIV-infected
ndividuals. Research ethics committees need to ensure equity
n distribution of beneﬁts and risks to all representatives of
ommunities [35]. Adequate proof of reasoning will need to
e submitted to the ethics committees if HIV-infected indi-
iduals were to be excluded from beneﬁting from health
nterventions which could potentially beneﬁt the participant/her
nfant.
Knowledge of HIV-incidence and local treatment guidelines
re essential when planning clinical trials. Maternal HIV infection
s associated with increased maternal illness and mortality and
ncreased risk of newborn adverse outcomes [36,37], which could
ncrease serious adverse event reporting. Transplacental transfer
f antibodies from mother to foetus is also negatively impacted by
aternal HIV infection [38].
Laboratory parameter (CD4+ and viral load) monitoring is essen-
ial during vaccine trials, to ensure that potential transient changes
39], do not increase risk to maternal or infant participant. Amend-
ents to treatment guidelines for HIV-infected pregnant women
n South Africa negated the requirement for routine CD4+ and viral
oad testing; therefore testing would need to be included as a study
rocedure.
Adverse reactions associated with antiretroviral therapy (e.g.
ephropathies associated with Tenofovir) may  lead to higher SAE
ate than expected.
.3.3. Malaria
There were 198 million cases of malaria and ∼584 000 malaria-
elated deaths in 2013 [40]. Malaria infection in pregnant women
s associated with maternal anaemia, an increased risk of preterm
irth and low birthweight infants [2,41] and a potential reduction
n transplacental transfer of antibodies from mother to foetus [38].
Intermittent preventative therapy with sulfadoxine-
yrimethamine during pregnancy (IPTp-SP) in high transmission
isk areas has been proven to prevent malaria and its complica-
ions [42] and is recommended by the World Health Organization.
lmost 60% of pregnant African women living in high risk areas
eceived at least one dose of ITPp-SP in 2013 [40].3 (2015) 6406–6412
Although malaria was  not a consideration in our studies, which
were performed in a non-endemic region, many LMIC are affected
by malaria, and ITPp-SP could be offered as a study participation
beneﬁt in endemic regions.
3.4. Adverse pregnancy outcomes
Poor foetal outcomes and neonatal death are important fac-
tors to monitor in maternal immunization trials. Almost half the
under-5 deaths globally in 2013 occurred in sub-Saharan Africa
[43]. Neonatal deaths account for 44% of under-5 deaths; 39.3% of
which take place in Southern Asia [43]. The stillbirth rates vary from
2 to 45/1000 births, with a global average of 19.1/1000 total births
[44]. Ninety-eight percent of stillbirths, which are closely related
to poverty, poor maternal education and rural residence, occur in
LMIC [44,45].
Safety review committees should compare adverse pregnancy
outcomes in vaccine and placebo recipients and to known local
background rates as a means of facilitating safety signal detection.
The data monitoring committee of Study A experienced a higher-
than expected work-load due to higher than anticipated incidence
of adverse pregnancy outcomes in study participants (7 stillbirths
in 317 deliveries).
3.5. Local practices
The custom of conﬁning the mother and newborn at home for
up to 6 weeks, to allow the mother regain her energy, is common in
LMIC [46,47]. Many post-partum women  in Africa will consult with
a traditional healer to aid in healing and protect against malicious
spirits [48,49]. Local customs around- and post-delivery should be
considered when preparing protocols for vaccine trials in pregnant
women. Conducting follow up visits at home and co-operation with
traditional healers may  reduce missed or late study-visits and loss
of trial participants to follow up. Loss-to-follow-up at any point
of a clinical trial proves to be challenging as results and expected
outcomes are altered, making the data collected less reliable and
accurate, as well as less generalizable to the rest of the original
population [50].
4. Conclusion
Immunization of pregnant women holds exciting prospects for
reduction of infections in pregnant women and their infants. Future
clinical trials are likely to be conducted in regions of the world
where disease burden and need for preventative measures are high,
but resources may  be limited.
Despite our study examples representing an urban centre
with good population coverage of access to facility-based obstet-
ric and neonatal care; many of the identiﬁed challenges are
broadly applicable to other LMIC settings. Challenges in con-
ducting RCT in LMIC include lack of reliable background data
on maternal and infant adverse events and paucity of local
investigators with experience in RCTs. Study design should be
conducted in collaboration with local investigators, and con-
sideration of available gestational age measurement facilities
and expertise, background diseases and customs is important.
Standardized case deﬁnitions for adverse events following immu-
nization of pregnant women  are being developed by the Brighton
Collaboration, and should be utilized in future protocol develop-
ment.
Beneﬁts of study participation should include recommended
health interventions, including micronutrient supplementation
and parasite treatment/prevention.
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Challenges
identiﬁed
Reasons for challenges Mitigation of
challenges
Accurate
gestational age
assessment
difﬁculties
Inaccurate last menstrual
period date recording due
to:
(i) Irregular menstrual
cycle length or amenorrhea
related to injectable
contraceptive use
(ii) Recall error
(iii) Unrecognised
miscarriages
Education of local
health care
workers and
community
Symphysis-fundal height
measurement discrepancy
due to:
(i) intra- and
inter-observer error
(ii) obesity
(iii) unrecognised multiple
pregnancies
Train local health
care providers on
palpation methods
Early ultrasound
assessment (US) not
available due to:
(i) no access to ultrasound
assessment
(ii) late presentation for
antenatal care (ANC)
(i) Encourage early
presentation for
ANC
(ii) Train and equip
local trial sites to
conduct basic US.
(ii) Consider
allowing use of US
results up to 28
weeks gestation
Enrolment
hampered by strict
inclusion and
exclusion criteria
Co-administration of
vaccines prohibited:
Certainty of relatedness of
adverse events to
vaccination with
investigational vaccine,
especially AEs occurring
close to vaccination date, is
questioned when other
vaccines are
co-administered at trial
enrolment
Remove all
co-administration
restriction
Offer
recommended
vaccines (e.g.
inﬂuenza, tetanus,
pertussis) as trial
beneﬁt
Gestational age window for
trial enrolment too narrow,
especially if
co-administration of other
vaccines is prohibited
Widen enrolment
window
Enrolment
hampered by
exclusion of
participants with
co-morbidities
Resistance to enrol women
with underlying or
co-morbid diseases on
trials, due to increase in
expected adverse events
Include
placebo-recipient
cohort for
comparison of
adverse eventsUnderestimation of
incidence of other diseases
in study population (e.g.
anaemia, malaria, HIV)
Gather background
population data on
disease burden
prior to trial
[3 (2015) 6406–6412 6411
Challenges
identiﬁed
Reasons for challenges Mitigation of
challenges
Sub-optimal
uptake of
recommended
vaccine use
Hesitancy by patients and
health care providers to
vaccinate pregnant women
Ignorance of disease risks
and vaccine beneﬁts
Make vaccine
safety data easily
available
Educate on risks of
disease and vaccine
safety
Assessment of
adverse events
Deﬁnitions of AEFI not well
developed for maternal
immunisation
Brighton
collaboration
developing
deﬁnitions which
should be used in
future protocols
Knowledge of background
rates of adverse pregnancy
outcomes
Engage with local
departments to
document local
rates of adverse
pregnancy
outcomes
Protocol deviations
due to timing of
scheduled visits
Local practices may
prevent participant from
attending study-speciﬁc
visit during certain times
(post delivery)
Knowledge of local
practices
Engage with
community leaders
when planning
visit schedule
Consider inclusion
of home visits
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